Vivos Therapeutics (VVOS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
21 Oct, 2026Executive summary
Virtual annual meeting scheduled for December 2, 2026; October 9, 2026 record date, with 33,609,393 common shares outstanding and one vote per share.
Ten proposals include director elections, executive pay and auditor votes, a reverse split, approvals for preferred-stock conversions and issuances, an equity-plan increase, and conversion to Nevada.
Voting matters and shareholder proposals
Board recommends FOR all seven director nominees and Proposals 2, 4–10; recommends a 3-year frequency for future say-on-pay votes.
Proposal 5 seeks authority for a 1-for-20 to 1-for-40 reverse split; Board would set the ratio and timing and may abandon it before effectiveness.
Proposal 6 seeks Nasdaq approval for up to 18,476,959 shares tied to Seneca-affiliated Series A preferred stock and warrants; potential issuance is ~55% of record-date common shares.
Proposal 7 seeks approval for up to 80 million shares on Series C conversion; Proposal 8 would add 4.9 million shares to the equity plan, raising its reserve from 4.1 million to 9 million.
Proposal 9 seeks conversion from Delaware to Nevada; Proposal 10 authorizes adjournment, if needed, to solicit votes on Proposals 5–9.
Board of directors and corporate governance
Seven nominees stand for election through the 2027 annual meeting; six directors are independent. R. Kirk Huntsman serves as both Chair and CEO; no lead independent director is designated.
Standing committees are Audit, Compensation, and Nominating and Corporate Governance; each operates under a written charter, and independent directors hold executive sessions.
In FY2025, the Board met eight times, Audit five times, Compensation five times, and Nominating and Corporate Governance did not meet; each then-serving director attended at least 75% of applicable meetings.
Nevada conversion would preserve one vote per common share, written consent, the 15% special-meeting right, an unclassified Board, and existing capital authorization; internal-affairs forum would shift to Nevada.
Latest events from Vivos Therapeutics
- Ballot combines seven director elections with major capital, equity-plan, and domicile proposals.VVOS
Proxy filing - Ten proposals include a reverse split, large preferred-stock issuances and Nevada conversion.VVOS
Proxy filing - A 10-proposal agenda puts dilution, Nasdaq compliance and Nevada conversion before stockholders.VVOS
Proxy filing - Q2 2026 revenue up 35% year-over-year, with improved gross margin but persistent net losses.VVOS
Q2 2026 - Capital-light, high-margin sleep apnea treatment model set for national expansion and rapid growth.VVOS
WTR Insights Conference: Powered by The Small Cap Showcase - Revenue up 70% in Q1 2026, but losses widened and Nasdaq delisting risk remains.VVOS
Q1 2026 - Registers 3.96M shares for resale from warrant exercises, supporting a provider-focused OSA strategy.VVOS
Registration filing - Q3 revenue up 17%, gross margin at 60%, with FDA clearance and financing needs ahead.VVOS
Q3 2024 - Revenue up 9%, operating loss down 35%, and FDA clearances and alliances drive 2025 growth.VVOS
Q4 2024